Events & Presentations

Presentations

a scientist with vials being tested

Earnings Presentations

Oct 30, 2024
Q3 2024 Biogen Earnings Presentation
Aug 01, 2024
Q2 2024 Biogen Earnings Presentation
Apr 24, 2024
Q1 2024 Biogen Earnings Presentation
Feb 13, 2024
Q4 and Full Year 2023 Biogen Earnings Presentation
Nov 08, 2023
Q3 2023 Biogen Earnings Presentation

Investor R&D Day 2021

Sep 21, 2021
Biogen 2021 Investor R&D Day
Sep 21, 2021
Biogen Digital Health
Sep 21, 2021
Advancements in Research
Sep 21, 2021
Alzheimer’s Disease Research Portfolio
Sep 21, 2021
Biogen Gene Therapy
Sep 21, 2021
Biomarkers
Sep 21, 2021
Biotherapeutics and Medicinal Sciences at Biogen
Sep 21, 2021
Human Genetics
Sep 21, 2021
Movement Disorders at Biogen
Sep 21, 2021
MS Portfolio

Conference and Other Investor Presentations

Jul 28, 2023
Proposed Acquisition of Reata Pharmaceuticals, Inc.
Dec 06, 2022
Biogen and Sage Zuranolone Webcast Presentation
Jan 13, 2022
Biogen Analyst Q&A Call
Jun 08, 2021
Biogen ADUHELM Launch
Oct 22, 2019
Aducanumab Update Presentation
Jun 05, 2019
Biogen ALS & R&D Portfolio Webcast Presentation
Mar 04, 2019
Biogen Planned Acquisition of Nightstar Therapeutics
Dec 12, 2018
Biogen MS & R&D Webcast Presentation
Jun 28, 2018
Biogen on R&D Progress Targeting Stroke

Medical and Scientific Conference Presentations

Apr 17, 2021
Aducanumab EMBARK study design audio presentation at AAN 2021
Apr 17, 2021
Aducanumab EMBARK study design poster at AAN 2021
Mar 13, 2021
Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD
Mar 13, 2021
Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD
Mar 10, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
Feb 23, 2021
Aducanumab data review with Global Alzheimer's Platform Foundation
Jan 14, 2021
Aducanumab data review and Q&A with Alzheimer's Disease International
Nov 04, 2020
Aducanumab EMBARK study design at CTAD 2020
Sep 23, 2020
Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation)
Sep 19, 2020
Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation)

Annual Stockholder Presentation

June 15, 2022
Biogen Annual Stockholder Presentation 2022

Hemophilia Spin-off Presentations

January 6, 2017
Bioverativ (BIVV) Analyst Day Presentation
May 3, 2016
Hemophilia Spin-off Presentation
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations